What are Biosimilar Antibodies?
Biosimilar antibodies are antibodies that are similar in structure and function to FDA-approved therapeutic antibodies. R&D Systems’ biosimilar antibodies are for research use only and are developed with recombinant antibody technology using the same sequence as the original therapeutic (reference) antibody. Biosimilars are a cost-effective alternative for assay development, facilitating development and validation of novel therapeutics. Our antibodies undergo rigorous testing to ensure equivalency and specific binding to the same molecule that is targeted by the therapeutic antibodies.
Our biosimilar antibodies are validated for a number of research applications such as flow cytometry, blocking/neutralizing, and immunocytochemistry. To meet your unique research needs, Bio-Techne offers biosimilar antibodies conjugated to Biotin, Alexa Fluor® 488, Alexa Fluor® 647, PE and more!
Featured Biosimilar Antibodies
| Target | Biosimilar Antibody |
| CD3 | Teplizumab |
| CD20 | Rituximab |
| CD52 | Alemtuzumab |
| EGFR | Cetuximab |
| ErbB2/Her2 | Trastuzumab |
| IL-5 | Mepolizumab |
| IL-6R alpha | Tocilizumab |
| Integrin alpha 4 beta 1 | Natalizumab |
| Integrin alpha 4 beta 7/LPAM-1 | Vedolizumab |
| PD-1 | Pembrolizumab |
| TNF-alpha | Adalimumab |
| VEGF | Bevacizumab |
| vWF | Caplacizumab |
Search All Biosimilar Antibodies
 |
||
|
Cytotoxicity Induced by Recombinant TNF-alpha is Neutralized by Human TNF-alpha (Adalimumab Biosimilar) Antibody. Recombinant Human TNF-alpha (Catalog # 210-TA) promotes cytotoxicity in the L-929 cell line in a dose-dependent manner (teal line), as measured by Resazurin (Catalog # AR002). The cytotoxicity elicited by Recombinant Human TNF-alpha is neutralized (purple line) by increasing concentrations of Human Anti-Human TNF-alpha (Research Grade Adalimumab Biosimilar) Monoclonal Antibody (Catalog # MAB9677). |
 |
||
|
Flow Cytometry Analysis of CD20 Detection in HEK293 Human cell line Transfected with Human CD20 and eGFP. HEK293 Human cell line was transfected with (A) Human CD20 or (B) irrelevant transfectants and eGFP, and cells were stained with Human Anti-Human CD20 (Rituximab Biosimilar) Monoclonal Antibody (Catalog # MAB9575) followed by APC-conjugated Anti-Human IgG Secondary Antibody (Catalog # F0135). |
Anti-Idiotype Antibodies
Complete your assay development with our anti-idiotype antibodies. Anti-idiotype antibodies bind to the highly variable, antigen binding region of another antibody. Bio-Techne’s range of anti-idiotype antibodies are specific for our biosimilar antibodies. We test the specificity and functionality of our anti-idiotype antibodies in combination with our biosimilars by performing bridging assays, blocking/binding inhibition, flow cytometry, and direct ELISA.
R&D Systems offers anti-idiotype antibodies designed for biosimilar antibodies. (Left) Diagram of a bridging assay with two anti-idiotype antibodies capturing a biosimilar antibody. (Right) Results from a bridging assay where the anti-idiotype antibody directed against Rituximab (Catalog # MAB9630) was used to specifically capture different concentrations of the biosimilar Rituximab (teal bars) , but did not capture, or bridge, Cetuximab (purple bar).